Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.

Hypocalcemia and an increase in creatinine level are the most important serious effects associated with foscarnet (PFA) therapy. In an animal model, we have explored the potential protective role of liposome-encapsulated foscarnet (LE-PFA) on these metabolic abnormalities. PFA administered as one bo...

Descripción completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Autores principales:	Omar, R F, Dusserre, N, Désormeaux, A, Poulin, L, Tremblay, M, Beauchamp, D, Bergeron, M G
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 1995
Materias:	Research Article
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162866/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8540701/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.9.1973
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!